The global Cell Therapy CMO market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Cell Therapy CMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Cell Therapy CMO market size and forecasts, in consumption value ($ Million), 2020-2031
Global Cell Therapy CMO market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Cell Therapy CMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Cell Therapy CMO market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Cell Therapy CMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Cell Therapy CMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Charles River, The Discovery Labs, BIOCENTRIQ, FUJIFILM Diosynth Biotechnologies, Exothera, WuXi AppTec, Pharmaron, OBiO, Cell Therapies, AGC Biologics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Cell Therapy CMO market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Stem Cell
Non-Stem Cell
麻豆原创 segment by Application
Commercial
Academic Research
Others
麻豆原创 segment by players, this report covers
Charles River
The Discovery Labs
BIOCENTRIQ
FUJIFILM Diosynth Biotechnologies
Exothera
WuXi AppTec
Pharmaron
OBiO
Cell Therapies
AGC Biologics
Cytiva
Helixmith
ThermoGenesis
Anemocyte
Thermo Fisher Scientific
CBM
Bio Elpida
Genezen
CCRM
RoslinCT
GenScript ProBio
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Cell Therapy CMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Cell Therapy CMO, with revenue, gross margin, and global market share of Cell Therapy CMO from 2020 to 2025.
Chapter 3, the Cell Therapy CMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Cell Therapy CMO market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Cell Therapy CMO.
Chapter 13, to describe Cell Therapy CMO research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Cell Therapy CMO by Type
1.3.1 Overview: Global Cell Therapy CMO 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Cell Therapy CMO Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Stem Cell
1.3.4 Non-Stem Cell
1.4 Global Cell Therapy CMO 麻豆原创 by Application
1.4.1 Overview: Global Cell Therapy CMO 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Commercial
1.4.3 Academic Research
1.4.4 Others
1.5 Global Cell Therapy CMO 麻豆原创 Size & Forecast
1.6 Global Cell Therapy CMO 麻豆原创 Size and Forecast by Region
1.6.1 Global Cell Therapy CMO 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Cell Therapy CMO 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Cell Therapy CMO 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Cell Therapy CMO 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Cell Therapy CMO 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Cell Therapy CMO 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Cell Therapy CMO 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Charles River
2.1.1 Charles River Details
2.1.2 Charles River Major Business
2.1.3 Charles River Cell Therapy CMO Product and Solutions
2.1.4 Charles River Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Charles River Recent Developments and Future Plans
2.2 The Discovery Labs
2.2.1 The Discovery Labs Details
2.2.2 The Discovery Labs Major Business
2.2.3 The Discovery Labs Cell Therapy CMO Product and Solutions
2.2.4 The Discovery Labs Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 The Discovery Labs Recent Developments and Future Plans
2.3 BIOCENTRIQ
2.3.1 BIOCENTRIQ Details
2.3.2 BIOCENTRIQ Major Business
2.3.3 BIOCENTRIQ Cell Therapy CMO Product and Solutions
2.3.4 BIOCENTRIQ Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 BIOCENTRIQ Recent Developments and Future Plans
2.4 FUJIFILM Diosynth Biotechnologies
2.4.1 FUJIFILM Diosynth Biotechnologies Details
2.4.2 FUJIFILM Diosynth Biotechnologies Major Business
2.4.3 FUJIFILM Diosynth Biotechnologies Cell Therapy CMO Product and Solutions
2.4.4 FUJIFILM Diosynth Biotechnologies Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
2.5 Exothera
2.5.1 Exothera Details
2.5.2 Exothera Major Business
2.5.3 Exothera Cell Therapy CMO Product and Solutions
2.5.4 Exothera Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Exothera Recent Developments and Future Plans
2.6 WuXi AppTec
2.6.1 WuXi AppTec Details
2.6.2 WuXi AppTec Major Business
2.6.3 WuXi AppTec Cell Therapy CMO Product and Solutions
2.6.4 WuXi AppTec Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 WuXi AppTec Recent Developments and Future Plans
2.7 Pharmaron
2.7.1 Pharmaron Details
2.7.2 Pharmaron Major Business
2.7.3 Pharmaron Cell Therapy CMO Product and Solutions
2.7.4 Pharmaron Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Pharmaron Recent Developments and Future Plans
2.8 OBiO
2.8.1 OBiO Details
2.8.2 OBiO Major Business
2.8.3 OBiO Cell Therapy CMO Product and Solutions
2.8.4 OBiO Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 OBiO Recent Developments and Future Plans
2.9 Cell Therapies
2.9.1 Cell Therapies Details
2.9.2 Cell Therapies Major Business
2.9.3 Cell Therapies Cell Therapy CMO Product and Solutions
2.9.4 Cell Therapies Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Cell Therapies Recent Developments and Future Plans
2.10 AGC Biologics
2.10.1 AGC Biologics Details
2.10.2 AGC Biologics Major Business
2.10.3 AGC Biologics Cell Therapy CMO Product and Solutions
2.10.4 AGC Biologics Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 AGC Biologics Recent Developments and Future Plans
2.11 Cytiva
2.11.1 Cytiva Details
2.11.2 Cytiva Major Business
2.11.3 Cytiva Cell Therapy CMO Product and Solutions
2.11.4 Cytiva Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Cytiva Recent Developments and Future Plans
2.12 Helixmith
2.12.1 Helixmith Details
2.12.2 Helixmith Major Business
2.12.3 Helixmith Cell Therapy CMO Product and Solutions
2.12.4 Helixmith Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Helixmith Recent Developments and Future Plans
2.13 ThermoGenesis
2.13.1 ThermoGenesis Details
2.13.2 ThermoGenesis Major Business
2.13.3 ThermoGenesis Cell Therapy CMO Product and Solutions
2.13.4 ThermoGenesis Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 ThermoGenesis Recent Developments and Future Plans
2.14 Anemocyte
2.14.1 Anemocyte Details
2.14.2 Anemocyte Major Business
2.14.3 Anemocyte Cell Therapy CMO Product and Solutions
2.14.4 Anemocyte Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Anemocyte Recent Developments and Future Plans
2.15 Thermo Fisher Scientific
2.15.1 Thermo Fisher Scientific Details
2.15.2 Thermo Fisher Scientific Major Business
2.15.3 Thermo Fisher Scientific Cell Therapy CMO Product and Solutions
2.15.4 Thermo Fisher Scientific Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.16 CBM
2.16.1 CBM Details
2.16.2 CBM Major Business
2.16.3 CBM Cell Therapy CMO Product and Solutions
2.16.4 CBM Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 CBM Recent Developments and Future Plans
2.17 Bio Elpida
2.17.1 Bio Elpida Details
2.17.2 Bio Elpida Major Business
2.17.3 Bio Elpida Cell Therapy CMO Product and Solutions
2.17.4 Bio Elpida Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 Bio Elpida Recent Developments and Future Plans
2.18 Genezen
2.18.1 Genezen Details
2.18.2 Genezen Major Business
2.18.3 Genezen Cell Therapy CMO Product and Solutions
2.18.4 Genezen Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 Genezen Recent Developments and Future Plans
2.19 CCRM
2.19.1 CCRM Details
2.19.2 CCRM Major Business
2.19.3 CCRM Cell Therapy CMO Product and Solutions
2.19.4 CCRM Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.19.5 CCRM Recent Developments and Future Plans
2.20 RoslinCT
2.20.1 RoslinCT Details
2.20.2 RoslinCT Major Business
2.20.3 RoslinCT Cell Therapy CMO Product and Solutions
2.20.4 RoslinCT Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.20.5 RoslinCT Recent Developments and Future Plans
2.21 GenScript ProBio
2.21.1 GenScript ProBio Details
2.21.2 GenScript ProBio Major Business
2.21.3 GenScript ProBio Cell Therapy CMO Product and Solutions
2.21.4 GenScript ProBio Cell Therapy CMO Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.21.5 GenScript ProBio Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Cell Therapy CMO Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Cell Therapy CMO by Company Revenue
3.2.2 Top 3 Cell Therapy CMO Players 麻豆原创 Share in 2024
3.2.3 Top 6 Cell Therapy CMO Players 麻豆原创 Share in 2024
3.3 Cell Therapy CMO 麻豆原创: Overall Company Footprint Analysis
3.3.1 Cell Therapy CMO 麻豆原创: Region Footprint
3.3.2 Cell Therapy CMO 麻豆原创: Company Product Type Footprint
3.3.3 Cell Therapy CMO 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Cell Therapy CMO Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Cell Therapy CMO 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Cell Therapy CMO Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Cell Therapy CMO 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Cell Therapy CMO Consumption Value by Type (2020-2031)
6.2 North America Cell Therapy CMO 麻豆原创 Size by Application (2020-2031)
6.3 North America Cell Therapy CMO 麻豆原创 Size by Country
6.3.1 North America Cell Therapy CMO Consumption Value by Country (2020-2031)
6.3.2 United States Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Cell Therapy CMO Consumption Value by Type (2020-2031)
7.2 Europe Cell Therapy CMO Consumption Value by Application (2020-2031)
7.3 Europe Cell Therapy CMO 麻豆原创 Size by Country
7.3.1 Europe Cell Therapy CMO Consumption Value by Country (2020-2031)
7.3.2 Germany Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Cell Therapy CMO Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Cell Therapy CMO Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Cell Therapy CMO 麻豆原创 Size by Region
8.3.1 Asia-Pacific Cell Therapy CMO Consumption Value by Region (2020-2031)
8.3.2 China Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Cell Therapy CMO Consumption Value by Type (2020-2031)
9.2 South America Cell Therapy CMO Consumption Value by Application (2020-2031)
9.3 South America Cell Therapy CMO 麻豆原创 Size by Country
9.3.1 South America Cell Therapy CMO Consumption Value by Country (2020-2031)
9.3.2 Brazil Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Cell Therapy CMO Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Cell Therapy CMO Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Cell Therapy CMO 麻豆原创 Size by Country
10.3.1 Middle East & Africa Cell Therapy CMO Consumption Value by Country (2020-2031)
10.3.2 Turkey Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Cell Therapy CMO 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Cell Therapy CMO 麻豆原创 Drivers
11.2 Cell Therapy CMO 麻豆原创 Restraints
11.3 Cell Therapy CMO Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Cell Therapy CMO Industry Chain
12.2 Cell Therapy CMO Upstream Analysis
12.3 Cell Therapy CMO Midstream Analysis
12.4 Cell Therapy CMO Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Charles River
The Discovery Labs
BIOCENTRIQ
FUJIFILM Diosynth Biotechnologies
Exothera
WuXi AppTec
Pharmaron
OBiO
Cell Therapies
AGC Biologics
Cytiva
Helixmith
ThermoGenesis
Anemocyte
Thermo Fisher Scientific
CBM
Bio Elpida
Genezen
CCRM
RoslinCT
GenScript ProBio
听
听
*If Applicable.
